Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has appointed Michael Zapolin as chief executive officer. Zapolin, known as "Zappy," will spearhead efforts to finance and list Unbuzzd on a stock exchange, followed by a nationwide commercial marketing and product rollout in the United States, according to the company. The transition to a publicly listed company is scheduled to go effective in the next quarter, with former CEO Richard Buzbuzian assisting in the process.
Unbuzzd markets unbuzzd(TM), a beverage designed to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms. The company said the product is backed by a peer-reviewed clinical study and is currently available through Amazon and its website. For investors tracking Quantum BioPharma, the full press release can be accessed at https://ibn.fm/CBNq1.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its over-the-counter version to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd and is entitled to royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The appointment of Zapolin comes as Unbuzzd prepares for a public listing, which could provide capital to scale operations and expand market reach. For Quantum BioPharma, the success of Unbuzzd could translate into significant royalty streams and enhance the value of its retained equity stake. The news is relevant to investors in the biopharmaceutical and consumer wellness sectors, as it signals potential growth in the functional beverage market aimed at mitigating alcohol's effects. The latest updates on Quantum BioPharma are available in the company's newsroom at https://ibn.fm/QNTM.
The announcement was disseminated by InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
